 Nabriva Therapeutics plc NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the BofA Securities 2020 Virtual Health Care Conference on Wednesday, May 13, at 11:00a.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETATM lefamulin, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia CABP. 